BioNTech SE Reports Q2 2025 Financial Results

TL;DR

BioNTech dropped Q2 2025 earnings and update on Aug 4th.

AI Summary

On August 4, 2025, BioNTech SE announced its second quarter 2025 financial results and provided a corporate update. The company is a German biotechnology firm focused on infectious disease and cancer immunotherapies.

Why It Matters

This filing provides investors with BioNTech's latest financial performance and strategic updates, crucial for evaluating the company's ongoing development and market position.

Risk Assessment

Risk Level: low — This is a routine financial results filing with no immediate indication of significant new risks.

Key Players & Entities

• BioNTech SE (company) — Registrant
• August 4, 2025 (date) — Date of press release
• 2025 (date) — Reporting period

FAQ

From the Filing

0001776985-25-000049.txt : 20250804 0001776985-25-000049.hdr.sgml : 20250804 20250804075702 ACCESSION NUMBER: 0001776985-25-000049 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 38 CONFORMED PERIOD OF REPORT: 20250804 FILED AS OF DATE: 20250804 DATE AS OF CHANGE: 20250804 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BioNTech SE CENTRAL INDEX KEY: 0001776985 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: 2M FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39081 FILM NUMBER: 251178047 BUSINESS ADDRESS: STREET 1: AN DER GOLDGRUBE 12 CITY: MAINZ STATE: 2M ZIP: 55131 BUSINESS PHONE: 0049613190840 MAIL ADDRESS: STREET 1: AN DER GOLDGRUBE 12 CITY: MAINZ STATE: 2M ZIP: 55131 6-K 1 form6-kq22025earningsprear.htm 6-K Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF AUGUST 2025 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20‑F or Form 40‑F: Form 20‑F ☒ Form 40‑F ☐ Indicate by check mark if the registrant is submitting the Form 6‑K in paper as permitted by Regulation S‑T Rule 101(b)(1): ☐ Indicate by check mark if the registrant is submitting the Form 6‑K in paper as permitted by Regulation S‑T Rule 101(b)(7): ☐ DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K On August 4, 2025, BioNTech SE (the “Company”) issued a press release announcing its second quarter 2025 financial results and corporate update and details of a conference call to be held at 8:00 am EDT on August 4, 2025 to discuss the results. The press release and the conference call presentation are attached as Exhibits 99.1 and 99.2, respectively, and incorporated by reference herein. The information contained in Exhibits 99.1 and 99.2 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, unless expressly set forth by specific reference in such a filing. SIGNATURE Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BioNTech SE By: /s/ Ramón Zapata-Gomez By: /s/ Dr. Sierk Poetting Name: Ramón Zapata-Gomez Name: Dr. Sierk Poetting Title: Chief Financial Officer Title: Chief Operating Officer Date: August 4, 2025 EXHIBIT INDEX Exhibit Description of Exhibit 99.1 BioNTech Announces Second Quarter 2025 Financial Results and Corporate Update 99.2 Second Quarter 2025: Corporate Update and Financial Results EX-99.1 2 a991bntxq22025pressrelease.htm EX-99.1 Document Exhibit 99.1 BioNTech Announces Second Quarter 2025 Financ ial Results and Corporate Update • Continued execution of BioNTech’s oncology strategy with focus on two pan-tumor programs including two announced transactions : mRNA-based cancer immunotherapy candidates and BNT327, a bispecific antibody candidate targeting PD-L1 1 and VEGF-A • Entered a global strategic co-development and co-commercialization collaboration with Bristol Myers Squibb (“BMS”) to jointly execute a broad clinical development program to evaluate and advance BNT327 across numerous solid tumor types • Announced strategic transaction to acquire CureVac N.V. (“Cu